RT Journal Article
T1 PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION.
A1 Tordrup, David
A1 Chouaid, Christos
A1 Cuijpers, Pim
A1 Dab, William
A1 van Dongen, Johanna Maria
A1 Espin, Jaime
A1 Jönsson, Bengt
A1 Léonard, Christian
A1 McDaid, David
A1 McKee, Martin
A1 Miguel, José Pereira
A1 Patel, Anita
A1 Reginster, Jean-Yves
A1 Ricciardi, Walter
A1 Rutten-van Molken, Maureen
A1 Rupel, Valentina Prevolnik
A1 Sach, Tracey
A1 Sassi, Franco
A1 Waugh, Norman
A1 Bertollini, Roberto
K1 Cost-effectiveness analysis
K1 Economic evaluation
K1 Expert opinion
K1 Methods
K1 Research agenda
AB The importance of economic evaluation in decision making is growing with increasing budgetary pressures on health systems. Diverse economic evidence is available for a range of interventions across national contexts within Europe, but little attention has been given to identifying evidence gaps that, if filled, could contribute to more efficient allocation of resources. One objective of the Research Agenda for Health Economic Evaluation project is to determine the most important methodological evidence gaps for the ten highest burden conditions in the European Union (EU), and to suggest ways of filling these gaps. The highest burden conditions in the EU by Disability Adjusted Life Years were determined using the Global Burden of Disease study. Clinical interventions were identified for each condition based on published guidelines, and economic evaluations indexed in MEDLINE were mapped to each intervention. A panel of public health and health economics experts discussed the evidence during a workshop and identified evidence gaps. The literature analysis contributed to identifying cross-cutting methodological and technical issues, which were considered by the expert panel to derive methodological research priorities. The panel suggests a research agenda for health economics which incorporates the use of real-world evidence in the assessment of new and existing interventions; increased understanding of cost-effectiveness according to patient characteristics beyond the "-omics" approach to inform both investment and disinvestment decisions; methods for assessment of complex interventions; improved cross-talk between economic evaluations from health and other sectors; early health technology assessment; and standardized, transferable approaches to economic modeling.
YR 2017
FD 2017-10-30
LK https://hdl.handle.net/10668/24633
UL https://hdl.handle.net/10668/24633
LA en
DS RISalud
RD Apr 6, 2025